Skip to main content
Clinical Medicine logoLink to Clinical Medicine
. 2002 Sep 1;2(5):465–473. doi: 10.7861/clinmedicine.2-5-465

Genetic profiling versus drug rotation in the optimisation of antihypertensive treatment

Isla S Mackenzie, Morris J Brown 1
PMCID: PMC4953090  PMID: 12448597

Abstract

There is a greater choice of drug classes for hypertension than most other diseases, increasing paradoxically the difficulty of finding the right drug for individual patients. Systematic drug rotation studies have shown that the rank order of response to different drugs varies substantially among patients. However, two broad patterns of response emerge, named after the initials of the major drug classes. The AB pattern is seen in Type 1 (high-renin) hypertensives. These are younger Caucasians who respond best to angiotensin-converting enzyme (ACE) inhibitors, angiotensin blockers and β-blockers. The CD pattern is seen in Type 2 (low-renin) patients. These are Afro-Caribbeans and older Caucasians, who respond best to calcium blockers and diuretics. This relative homogeneity of phenotype at each age group contrasts with a large heterogeneity of genotype on recent genome-wide scans, and suggests that most hypertension is due to interaction among multiple minor genetic variants. Genotype is unlikely therefore to be useful in selecting treatment for most patients. The exception is patients who have the atypical phenotype for their age, illustrated by the rare Na+ dependent monogenic syndromes of the young.

Keywords: aldosterone, cross-over study, hypertension, pharmacogenetics, spironolactone

Full Text

The Full Text of this article is available as a PDF (325.6 KB).


Articles from Clinical Medicine are provided here courtesy of Royal College of Physicians

RESOURCES